Literature DB >> 7611221

Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt.

L Spahr1, D Fenyves, V V N'Guyen, L Roy, L Legault, M P Dufresne, G Pomier-Layrargues.   

Abstract

Hepatorenal syndrome (HRS) is a functional renal failure occurring in advanced liver cirrhosis with ascites. It is due to renal cortical vasoconstriction resulting from complex hemodynamic disturbances related to cirrhosis and portal hypertension. There is no consistently effective therapy except for liver transplantation. We report a case of severe HRS in a patient with advanced liver cirrhosis and portal hypertension. Three sessions of hemodialysis were performed because of severe renal failure (serum urea 83 mg/dl, serum creatinine 6 mg/dl). Creation of an intrahepatic portosystemic shunt reduced the portocaval gradient from 18 to 7 mm Hg. Spectacular improvement of the renal function was observed soon after the procedure, with spontaneous recovery of diuresis and a return of serum urea and creatinine to baseline values. The patient unfortunately died 2 months later from adult respiratory distress syndrome post emergency surgery for a massive bleed related to a duodenal ulcer. Throughout this episode, the renal function remained stable. The postmortem examination showed histologically normal kidneys. We conclude that the intrahepatic portosystemic shunt can improve renal function in cirrhotic patients with HRS; it could be used in patients awaiting liver transplantation to reverse preoperative renal failure.

Entities:  

Mesh:

Year:  1995        PMID: 7611221

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

2.  Hepatorenal syndrome.

Authors:  Bimaljit Singh Sandhu; Arun J Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

Review 3.  Recent advances in our understanding of hepatorenal syndrome.

Authors:  Florence Wong
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-22       Impact factor: 46.802

4.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Authors:  K A Brensing; J Textor; J Perz; P Schiedermaier; P Raab; H Strunk; H U Klehr; H J Kramer; U Spengler; H Schild; T Sauerbruch
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

5.  Renal haemodynamics and function following partial portal decompression.

Authors:  Sharona Ross; Donald Thometz; Francesco Serafini; Mark Bloomston; Connor Morton; Emmanuel Zervos; Alexander Rosemurgy
Journal:  HPB (Oxford)       Date:  2009-05       Impact factor: 3.647

Review 6.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02

7.  Hepatorenal syndrome: current management.

Authors:  Florence Wong
Journal:  Curr Gastroenterol Rep       Date:  2008-02

8.  The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status.

Authors:  Gilles Pomier-Layrargues; Louis Bouchard; Michel Lafortune; Julien Bissonnette; Dave Guérette; Pierre Perreault
Journal:  Int J Hepatol       Date:  2012-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.